Mechanistic insights into the versatile stoichiometry and biased signaling of the apelin receptor-arrestin complex.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 40790299.
- Also identified by DOI 10.1038/s41467-025-62870-z and PMC identifier 12339924.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The apelin receptor (APJR) plays a pivotal role in regulating cardiovascular and metabolic health<sup>1,2</sup>. Understanding the mechanisms of biased agonism at APJR is crucial for drug discovery, as stimulation of the β-arrestin pathway may lead to some adverse effects<sup>3</sup>. Structural analyses of APJR-Gi complexes have clarified the structural basis of receptor dimerization and activation<sup>4,5</sup>, yet the absence of structural data on APJR-arrestin complexes has impeded a comprehensive understanding of APJR stoichiometry in the dual signaling pathways and biased agonism. Here, we present APJR-β-arrestin1 structures bound to a clinical drug analog, revealing 2:2 and 2:1 stoichiometries associated with differential β-arrestin recruitment. Through comparison of the two transducer-coupled APJR structures bound to the same ligand, we identify key residues and motifs crucial for directing biased signaling. These findings highlight APJR's versatile stoichiometry in coupling with β-arrestin and Gi proteins, establishing a framework for understanding biased agonism and guiding the development of therapeutics.
Medical subject headings
- Apelin Receptors
- Signal Transduction
- beta-Arrestin 1